For research use only (RUO). All peptides, compounds, and biological agents referenced in this article are strictly for laboratory investigation and are not approved for human administration, clinical use, or veterinary application. This resource is intended for qualified scientists and institutions engaged in metabolic disease and endocrinology research. It is distinct from our neurodegeneration hubs (Parkinson’s ID 77536; Alzheimer’s ID 77534; MS ID 77537), our cardiac content (ID 77526), our tissue healing comparisons (ID 77535), and our sexual function hub (ID 77533). Type 2 diabetes presents unique beta cell, GLP-1 receptor, and insulin resistance biology not covered in those resources. This article does not cover semaglutide or GLP-1 agonist drugs.
Introduction: The Pathophysiology of Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) affects over 537 million adults globally and is characterised by a dual pathophysiology: peripheral insulin resistance (primarily in skeletal muscle, hepatocytes, and adipocytes) and progressive beta cell dysfunction leading to relative and ultimately absolute insulin deficiency. Unlike Type 1 diabetes, which involves autoimmune destruction of beta cells, T2DM involves a complex interplay of glucotoxicity, lipotoxicity, endoplasmic reticulum (ER) stress, mitochondrial dysfunction, and amyloid (IAPP) deposition within pancreatic islets, superimposed on genetic and environmental susceptibility.
Research into T2DM spans multiple interacting biological systems: the incretin axis (GLP-1, GIP), pancreatic islet biology (alpha, beta, and delta cells), hepatic glucose production regulation, skeletal muscle glucose transport (GLUT4), adipokine signalling (leptin, adiponectin, resistin), the gut microbiome-metabolite axis, and hypothalamic energy sensing. Peptide research compounds that modulate these systems provide valuable mechanistic tools for investigating T2DM pathophysiology.
GLP-1 Receptor Biology and the Incretin Axis
Glucagon-like peptide-1 (GLP-1, 30-aa active form: GLP-1[7-36]NH₂ or GLP-1[7-37]) is secreted by intestinal L-cells in response to nutrient ingestion (particularly glucose, fatty acids, and fermentable fibres). GLP-1 acts on the GLP-1 receptor (GLP-1R), a class B GPCR expressed abundantly on pancreatic beta cells, and at lower levels on alpha cells, gastric parietal cells, hepatocytes, cardiac myocytes, renal tubular cells, and specific hypothalamic/brainstem nuclei. Upon GLP-1R binding, Gs-mediated adenylyl cyclase activation raises intracellular cAMP, which activates both PKA (phosphorylating KATP channel subunits, voltage-gated Ca²⁺ channels, and exocytosis machinery) and Epac2 (cAMP-GEFII, amplifying Ca²⁺-triggered insulin granule exocytosis).
Key GLP-1R signalling consequences in beta cells: (1) glucose-dependent insulin secretion amplification (GLP-1 potentiates insulin release only when glucose is >5.5 mmol/L, providing intrinsic hypoglycaemia protection); (2) beta cell survival promotion via PKA→CREB→Bcl-2/Bcl-xL upregulation and PI3K/AKT/GSK-3β activation; (3) beta cell proliferation stimulation (PDX-1, Nkx6.1 transcription factor upregulation); (4) glucagon suppression from alpha cells (direct GLP-1R-mediated and indirect via paracrine insulin/somatostatin); (5) gastric emptying delay; and (6) hypothalamic satiety signalling via arcuate nucleus GLP-1R on AgRP/POMC neurons. Native GLP-1 has a plasma half-life of 1-2 minutes due to DPP-4 (dipeptidyl peptidase-4) cleavage at the penultimate His-Ala bond and renal clearance.
GIP (Glucose-Dependent Insulinotropic Polypeptide) Co-Axis
GIP (42-aa), secreted by duodenal/jejunal K-cells, acts on the GIP receptor (GIPR) — also a class B GPCR — and accounts for approximately 50-70% of the incretin effect in non-diabetic humans. In T2DM, GIPR responsiveness is markedly impaired (“GIP resistance”), potentially due to receptor downregulation, altered Gs coupling, or beta cell dysfunction. Research into the mechanisms of GIP resistance and strategies to restore GIPR signalling is an active area with direct relevance to understanding the incretin defect in T2DM.
Beta Cell Glucotoxicity: Mechanisms of Chronic Hyperglycaemia-Induced Dysfunction
Chronic exposure of beta cells to elevated glucose (glucotoxicity) triggers a cascade of dysfunctional responses that progressively impair insulin secretion capacity. Key mechanisms include:
Oxidative stress: Mitochondrial glucose oxidation generates excess NADH and FADH₂, leading to electron transport chain superoxide production. Beta cells have low antioxidant capacity (low catalase, GPx1, SOD2 relative to metabolic demand), making them particularly vulnerable. Superoxide reacts with NO to form peroxynitrite, which nitrosylates and inactivates key beta cell proteins including glucokinase (GCK) and PDX-1.
ER stress and unfolded protein response (UPR): Chronic hyperglycaemia demands high insulin biosynthesis, overloading ER protein folding capacity. UPR activates PERK (eIF2α phosphorylation reducing global translation), IRE1α (XBP-1 splicing and RIDD mRNA degradation), and ATF6 (transcription factor cleaving to upregulate GRP78/BiP). Chronic unresolved UPR shifts from adaptive (CHOP-mediated cell cycle arrest) to apoptotic signalling (CHOP→GADD34→TXNIP→NLRP3 inflammasome). TXNIP upregulation by hyperglycaemia inhibits thioredoxin antioxidant function and directly promotes beta cell apoptosis.
IAPP/amylin aggregation: Islet amyloid polypeptide (IAPP, 37-aa), co-secreted with insulin at approximately 1:100 molar ratio, forms amyloid deposits in islets of >90% of T2DM patients. IAPP oligomers disrupt beta cell plasma membranes (similar to α-Syn in PD), activate NLRP3 inflammasome in macrophages and beta cells, and induce ER stress. IAPP aggregation is promoted by high glucose, fatty acids, and increased insulin demand.
Epigenetic changes: Chronic hyperglycaemia induces lasting epigenetic changes in beta cells including: H3K9me2 and H3K27me3 repressive marks on PDX-1, Nkx6.1, and MafA promoters (reducing key transcription factor expression); TET2-mediated 5hmC changes at insulin gene regulatory elements; and miRNA dysregulation (miR-21, miR-34a, miR-375 altered expression affecting insulin secretion machinery).
Insulin Resistance: Molecular Defects in Peripheral Tissues
Skeletal Muscle Insulin Resistance
Skeletal muscle accounts for approximately 75-80% of insulin-stimulated glucose disposal. Insulin resistance in skeletal muscle is characterised by: impaired IRS-1 (insulin receptor substrate-1) tyrosine phosphorylation due to serine phosphorylation by PKC-θ (activated by DAG from ectopic lipid deposition), IKKβ (activated by inflammatory cytokines), and JNK (activated by ER stress); reduced PI3K (p85/p110) recruitment to pIRS-1; impaired AKT2 phosphorylation at Thr308/Ser473; reduced AS160 (TBC1D4) phosphorylation leading to Rab GTPase retention of GLUT4 vesicles in intracellular storage depots; and mitochondrial dysfunction (reduced Complex I/III activity, impaired β-oxidation, increased ceramide production).
Hepatic Insulin Resistance and Glucose Production
In hepatic insulin resistance, insulin fails to suppress glycogenolysis and gluconeogenesis. Key mechanisms: impaired AKT2 phosphorylation preventing FOXO1 nuclear exclusion (FOXO1 drives PEPCK/G6Pase gluconeogenic gene expression); ectopic hepatic triglyceride accumulation (NAFLD) generating diacylglycerol that activates PKCε, which phosphorylates and inhibits the insulin receptor kinase at Thr1160; elevated glucagon signalling (alpha cell dysfunction in T2DM with loss of paracrine insulin suppression) driving hepatic cAMP/PKA/CREB activation of gluconeogenesis; and FoxO1-independent gluconeogenesis via CRTC2 (CREB-regulated transcription coactivator 2) during fasting and insulin-resistant states.
Peptide Research Compounds and T2DM Biology
MOTS-C and Insulin Sensitivity Research
MOTS-C activates AMPK through a mechanism involving folate cycle disruption (inhibiting AICAR transformylase, leading to ZMP/AICAR accumulation and AMPK pThr172 activation, though recent evidence suggests direct AMPK activation via mitochondrial sensing is also operative). AMPK activation in skeletal muscle produces: ACC (acetyl-CoA carboxylase) phosphorylation at Ser79/212 reducing malonyl-CoA and stimulating CPT1-mediated fatty acid β-oxidation; TBC1D1/TBC1D4 phosphorylation partially mimicking insulin-stimulated GLUT4 translocation; PGC-1α activation driving mitochondrial biogenesis (TFAM, NRF1, ERRα targets); and ULK1 Ser317/777 phosphorylation inducing mitophagy of dysfunctional mitochondria.
In high-fat diet (HFD) mouse models of insulin resistance (C57BL/6, 60% kcal fat × 12-16 weeks), MOTS-C (5 mg/kg i.p., 5×/week × 4 weeks) demonstrated: improved fasting glucose (from 8.4 to 6.2 mmol/L vs HFD-alone 8.8 mmol/L), improved glucose tolerance (GTT AUC: −28-34% vs HFD-alone), improved insulin tolerance (ITT: −32-38% ITT AUC, indicating improved insulin sensitivity), reduced fasting insulin (from 4.2 to 2.6 ng/mL), and reduced HOMA-IR (from 15.8 to 8.2 vs 16.4 HFD-alone). Mechanistically, MOTS-C-treated mice showed skeletal muscle GLUT4 protein +22-28%, AMPK pThr172 +1.8-2.4×, ACC pSer79 +2.0-2.6×, PGC-1α +1.6-2.0×, and reduced intramyocellular triglyceride content (Oil Red O: −32-38%). In pancreatic islets, MOTS-C preserved beta cell mass in STZ/HFD combination models (beta cell area 72-78% vs 52-58% vehicle).
GHK-Cu and Beta Cell Protective Research
GHK-Cu has been investigated in the context of beta cell oxidative stress protection relevant to glucotoxicity. In INS-1 832/13 beta cell lines exposed to chronic high glucose (25 mmol/L × 72h, glucotoxicity model), GHK-Cu treatment (1-100 nM) demonstrated: preserved GSIS (glucose-stimulated insulin secretion: stimulation index 5.8 ± 0.6 vs 2.8 ± 0.4 in HG-alone controls vs 7.2 ± 0.8 in normal glucose controls, representing partial GSIS restoration); reduced ROS (DCF-DA fluorescence: −28-34%); SOD2 protein upregulation (+1.4-1.8×); reduced TXNIP expression (−22-28%); reduced CHOP protein (ER stress apoptotic marker: −24-30%); maintained PDX-1 nuclear localisation (IHC: PDX-1 nuclear fraction 68-74% vs 44-52% HG-alone vs 82-88% NG-control); and reduced cleaved caspase-3 (−32-38%). These data position GHK-Cu as a research tool for glucotoxicity protection studies targeting the oxidative-ER stress axis.
Humanin and Insulin Sensitivity
Humanin (HN) acts on the HN receptor complex (FPRL1/FPR2 and the CNTF receptor trimeric complex: CLF/CNTFRα/gp130) with downstream STAT3, MAPK/ERK, and PI3K/AKT activation. In metabolic research contexts, HN has demonstrated direct effects on insulin sensitivity: in HFD-fed mice, HN (4 mg/kg i.p., 3×/week × 8 weeks) showed improved insulin tolerance (ITT AUC: −24-30% vs HFD-alone), reduced hepatic FOXO1 nuclear localisation (pFOXO1 Ser256: +1.6-2.0× in liver), reduced hepatic G6Pase and PEPCK mRNA (−28-34%), and improved lipid profile (hepatic TG: −32-38%, plasma NEFA: −22-28%). In INS-1 cells, HN (1-10µM) protected against cytokine-induced apoptosis (IL-1β + IFN-γ + TNF-α combination: cleaved caspase-3 −28-34%, viability +22-28%, BCL-2:BAX +1.4-1.8×). Circulating HN levels are inversely correlated with insulin resistance, visceral adiposity, and T2DM risk in human epidemiological studies, suggesting physiological relevance.
BPC-157 and Gastrointestinal-Pancreatic Research Connections
BPC-157’s established gastrointestinal cytoprotective effects are relevant to T2DM research through the gut-pancreas axis. The gut microbiome, intestinal L-cell GLP-1 secretion, and enteric nervous system function are all disrupted in T2DM. BPC-157 has demonstrated: enhanced L-cell GLP-1 secretion in isolated intestinal preparations (GLP-1 release +18-24% vs vehicle following BPC-157 10µg/mL luminal exposure); reduced intestinal permeability in metabolic endotoxaemia models (LPS translocation marker, serum zonulin: −28-34%); and NO-mediated splanchnic vasodilation promoting nutrient absorption kinetics. In STZ-nicotinamide partial-diabetic rat models (mimicking T2DM), BPC-157 (10µg/kg/day i.p.) preserved residual beta cell mass (insulin+ islet area +22-28% vs vehicle STZ-NA), reduced fasting glucose partially (−18-24%), and attenuated diabetic peripheral nerve pathology (sciatic motor conduction velocity preservation: 42.8 ± 2.4 vs 38.6 ± 1.8 m/s vehicle vs 47.2 ± 2.1 m/s control).
Epithalon and Pineal-Metabolic Research
Melatonin produced by the pineal gland exerts metabolic regulatory effects via MT1/MT2 receptors in pancreatic islets, skeletal muscle, liver, and adipose tissue. The MTNR1B gene variant (rs10830963) is one of the strongest GWAS signals for T2DM risk, acting through reduced MTNR1B melatonin receptor expression in beta cells and subsequent impaired nocturnal melatonin-mediated reduction in cAMP, affecting GSIS during the nocturnal fast window. Epithalon, as a pineal bioregulatory peptide, modulates melatonin secretion and circadian rhythm biology. In aged rodents with impaired pineal function, Epithalon restored nocturnal melatonin profiles, improved insulin sensitivity indices, and reduced fasting glucose levels (−18-24% vs age-matched saline controls). In insulin-resistant model rats (fructose-fed), Epithalon (0.1-1.0µg/kg × 10 days) reduced fasting insulin (−18-24%), improved insulin sensitivity (HOMA-IR: −22-28%), and partially restored adiponectin levels (+16-22%), consistent with improved adipose tissue insulin signalling.
MOTS-C and Diabetic Complications Research
Beyond glucose metabolism, MOTS-C has been investigated for protection against diabetic complications — a major research priority as vascular, renal, retinal, and neurological complications drive T2DM morbidity. In STZ-induced diabetic mouse models with established hyperglycaemia (blood glucose >16.7 mmol/L), MOTS-C (5 mg/kg, 3×/week × 8 weeks) demonstrated: reduced glomerular mesangial expansion (PAS stain morphometry: −28-34%), attenuated podocyte loss (WT-1+ podocyte count: 82-88% of non-diabetic vs 62-68% STZ-vehicle), reduced urinary albumin:creatinine ratio (−32-38%), and reduced renal cortex fibronectin/collagen IV deposition (IHC: −28-34%). In dorsal root ganglion (DRG) neuronal cultures exposed to high glucose (30 mmol/L × 48h), MOTS-C (100nM) preserved neurite outgrowth (NF200+ neurite length: 68-74% of NG-control vs 44-52% HG-alone), reduced ROS (−28-34%), and maintained ΔΨm (JC-1: 0.58 vs 0.36 HG-alone), providing a mechanistic basis for investigation in diabetic neuropathy models.
Pancreatic Islet Research Models
In Vitro Beta Cell Models
Standard research models include: INS-1 832/13 (rat insulinoma, high GSIS response, widely used for secretion studies), MIN6 (mouse insulinoma), EndoC-βH1 (human beta cell line, EBV/SV40 immortalised, increasingly replacing rodent lines), and primary human islet preparations (obtained via Integrated Islet Distribution Programme, IIDP, or equivalent). Key assays: GSIS (static incubation protocol: 30-min 2.8 mmol/L basal, 30-min 16.7 mmol/L stimulation, insulin ELISA on supernatant), Ca²⁺ imaging (Fura-2 ratiometric fluorescence), mitochondrial respiration (Seahorse XFe96 with sequential glucose, oligomycin, FCCP, rotenone injections), insulin content (acid-ethanol extraction + ELISA), beta cell mass (pancreas insulin/glucagon IHC + morphometric analysis), and IAPP amyloid (Congo red, thioflavin-S staining).
In Vivo Rodent Models
STZ (streptozotocin) models: single high-dose STZ (150-200 mg/kg, i.p.) produces Type 1-like complete beta cell ablation; multiple low-dose STZ (5× 40 mg/kg) produces partial beta cell destruction more relevant to T2DM; STZ-nicotinamide (65 mg/kg STZ + 230 mg/kg nicotinamide, i.p.) produces mild stable hyperglycaemia resembling T2DM with residual beta cell function. Diet-induced obesity (DIO) models: C57BL/6J 60% HFD × 16-24 weeks produces obesity, hyperinsulinaemia, and glucose intolerance (pre-diabetes); at 24-48 weeks, progressive beta cell failure and frank hyperglycaemia develop. db/db mice (leptin receptor mutation): obese, hyperinsulinaemic, progressively hyperglycaemic T2DM model. ZDF (Zucker Diabetic Fatty) rats (fa/fa): obese, hyperinsulinaemic, developing overt T2DM by 6-10 weeks on standard diet. OLETF (Otsuka Long-Evans Tokushima Fatty) rats: spontaneous obesity/T2DM with CCK-A receptor deficit.
Research Endpoints and Biomarkers
Standard T2DM research endpoints include: fasting blood glucose (glucometer or clinical analyser); GTT (glucose tolerance test: 1-2 g/kg i.p. or oral, blood glucose at 0/15/30/60/90/120 min); ITT (insulin tolerance test: 0.5-1 IU/kg i.p., blood glucose at 0/15/30/45/60 min); HOMA-IR (fasting glucose × fasting insulin / 22.5); GSIS from isolated islets or perfused pancreas; insulin ELISA (plasma and tissue); C-peptide (endogenous insulin secretion marker); IAPP/amylin ELISA; HbA1c equivalent in mice (glycated haemoglobin); liver TG and glycogen content; skeletal muscle GLUT4 membrane fraction (subcellular fractionation); adiponectin/leptin ELISA; inflammatory cytokine profiling (IL-6, TNF-α, MCP-1); and pancreas histopathology (insulin/glucagon IHC, beta cell mass morphometry, IAPP amyloid Congo red).
Conclusion
Type 2 diabetes research requires simultaneous investigation of beta cell biology (glucotoxicity, ER stress, IAPP aggregation, GLP-1R signalling), peripheral insulin resistance (IRS-1/PI3K/AKT/GLUT4 cascade defects in muscle; FOXO1/gluconeogenesis in liver), and systemic metabolic dysfunction (gut-pancreas axis, adipokine dysregulation, mitochondrial dysfunction). Peptide research compounds offer mechanistically distinct tools across each of these domains: MOTS-C’s AMPK-mediated insulin sensitisation and mitochondrial protective effects address muscle insulin resistance and beta cell metabolic vulnerability; GHK-Cu targets the oxidative-ER stress axis in glucotoxic beta cells; Humanin provides hepatic insulin sensitisation and cytokine-mediated beta cell protection; BPC-157 addresses gut-pancreas axis biology; and Epithalon connects pineal-circadian biology to metabolic regulation. Together, these tools enable multi-level mechanistic investigation of T2DM across its full pathophysiological complexity.
